ARD-2585 - CAS 2757422-79-8

ARD-2585 is an exceptionally potent and orally active PROTAC degrader of androgen receptor for the treatment of advanced prostate cancer.

* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.

Molecular Formula
C41H43ClN8O5
Molecular Weight
763.28

ARD-2585

    • Specification
      • Solubility
        Soluble in DMSO
        Storage
        Store at -20°C
        IUPAC Name
        N-[(1r,4r)-4-(3-chloro-4-cyano-N-methylanilino)cyclohexyl]-4-[4-[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]azetidin-3-yl]piperazin-1-yl]benzamide
        Synonyms
        Benzamide, N-[trans-4-[(3-chloro-4-cyanophenyl)methylamino]cyclohexyl]-4-[4-[1-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-3-azetidinyl]-1-piperazinyl]-; N-((1r,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohexyl)-4-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)azetidin-3-yl)piperazin-1-yl)benzamide; N-[trans-4-[(3-Chloro-4-cyanophenyl)methylamino]cyclohexyl]-4-[4-[1-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-3-azetidinyl]-1-piperazinyl]benzamide; ARD 2585; ARD2585
    • Properties
      • Boiling Point
        1032.7±65.0°C at 760 Torr
        Density
        1.46±0.1 g/cm3
        InChI Key
        LUCHABJUYSYJAT-RVWRWSNSNA-N
        InChI
        InChI=1S/C41H43ClN8O5/c1-46(30-9-4-26(22-43)35(42)21-30)28-10-5-27(6-11-28)44-38(52)25-2-7-29(8-3-25)47-16-18-48(19-17-47)32-23-49(24-32)31-12-13-33-34(20-31)41(55)50(40(33)54)36-14-15-37(51)45-39(36)53/h2-4,7-9,12-13,20-21,27-28,32,36H,5-6,10-11,14-19,23-24H2,1H3,(H,44,52)(H,45,51,53)/t27-,28-,36?
        Canonical SMILES
        N#CC1=CC=C(C=C1Cl)N(C)C2CCC(NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C5CN(C6=CC=C7C(=O)N(C(=O)C7=C6)C8C(=O)NC(=O)CC8)C5)CC2
    • Reference Reading
      • 1. Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
        Hoda Metwally,Bukeyan Miao,Weiguo Xiang,Aleksas Matvekas,Miao He,Bo Wen,Lu Wang,Yu Wang,Paul D Kirchhoff,Duxin Sun,Shaomeng Wang,Xin Han,Lijie Zhao,Chong Qin,Donna McEachern J Med Chem . 2021 Sep 23;64(18):13487-13509. doi: 10.1021/acs.jmedchem.1c00900.
        We report herein the discovery of exceptionally potent and orally bioavailable PROTAC AR degraders with ARD-2585 being the most promising compound. ARD-2585 achieves DC50values of ≤0.1 nM in the VCaP cell line with AR gene amplification and in the LNCaP cell line carrying an AR mutation. It potently inhibits cell growth with IC50values of 1.5 and 16.2 nM in the VCaP and LNCaP cell lines, respectively, and achieves excellent pharmacokinetics and 51% of oral bioavailability in mice. It is more efficacious than enzalutamide in inhibition of VCaP tumor growth and does not cause any sign of toxicity in mice. ARD-2585 is a promising AR degrader for extensive investigations for the treatment of advanced prostate cancer.
Bio Calculators
Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g
Related Products
BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
  • Email:
Inquiry Basket